CO2021005051A2 - Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas - Google Patents

Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas

Info

Publication number
CO2021005051A2
CO2021005051A2 CONC2021/0005051A CO2021005051A CO2021005051A2 CO 2021005051 A2 CO2021005051 A2 CO 2021005051A2 CO 2021005051 A CO2021005051 A CO 2021005051A CO 2021005051 A2 CO2021005051 A2 CO 2021005051A2
Authority
CO
Colombia
Prior art keywords
glp1
gdf15
peptide
fusion proteins
glucagon
Prior art date
Application number
CONC2021/0005051A
Other languages
English (en)
Spanish (es)
Inventor
Chichi Huang
Jennifer Furman
Xiefan Lin-Schmidt
Shamina Rangwala
Shannon Mullican
Matthew M Rankin
Songmao Zheng
Serena M Nelson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70330680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2021005051(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2021005051A2 publication Critical patent/CO2021005051A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2021/0005051A 2018-10-22 2021-04-20 Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas CO2021005051A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862748603P 2018-10-22 2018-10-22
PCT/IB2019/059029 WO2020084496A1 (en) 2018-10-22 2019-10-22 Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
CO2021005051A2 true CO2021005051A2 (es) 2021-04-30

Family

ID=70330680

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0005051A CO2021005051A2 (es) 2018-10-22 2021-04-20 Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas

Country Status (24)

Country Link
US (3) US11713345B2 (cg-RX-API-DMAC10.html)
EP (2) EP4520343A3 (cg-RX-API-DMAC10.html)
JP (2) JP7539902B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210081389A (cg-RX-API-DMAC10.html)
CN (2) CN119751697A (cg-RX-API-DMAC10.html)
AU (2) AU2019368816B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021007376A2 (cg-RX-API-DMAC10.html)
CA (1) CA3116983A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021000987A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021005051A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210193A (cg-RX-API-DMAC10.html)
DO (1) DOP2021000075A (cg-RX-API-DMAC10.html)
EA (1) EA202191105A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP21028914A (cg-RX-API-DMAC10.html)
ES (1) ES3011982T3 (cg-RX-API-DMAC10.html)
IL (1) IL282297B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20210084A1 (cg-RX-API-DMAC10.html)
MX (1) MX428581B (cg-RX-API-DMAC10.html)
MY (1) MY205905A (cg-RX-API-DMAC10.html)
PE (1) PE20211078A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021550885A1 (cg-RX-API-DMAC10.html)
SA (1) SA521421825B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202103990QA (cg-RX-API-DMAC10.html)
WO (1) WO2020084496A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN113474363A (zh) * 2018-11-20 2021-10-01 詹森药业有限公司 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
JP7536030B2 (ja) * 2019-03-08 2024-08-19 アムジエン・インコーポレーテツド 増殖分化因子15併用療法
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
EP4619423A1 (en) * 2022-11-18 2025-09-24 Yuhan Corporation Dual function proteins and uses thereof
CN116813742A (zh) * 2022-11-22 2023-09-29 杭州博茵生物技术有限公司 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用
WO2024144431A1 (ru) * 2022-12-29 2024-07-04 Авва Фармасьютикалс Лтд Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
JP2026505740A (ja) * 2023-01-20 2026-02-18 コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー Gfralを標的にするアンチセンスオリゴマー及びこの用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
KR20090039787A (ko) 2006-07-18 2009-04-22 센토코 인코포레이티드 인간 glp-1 모방체, 조성물, 방법 및 용도
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
CA2740632A1 (en) 2008-10-31 2010-05-06 St. Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
MX2011007889A (es) 2009-02-06 2011-08-15 Syngenta Participations Ag Modificacion de enzima multidominio para la expresion en plantas.
TW201101990A (en) 2009-07-08 2011-01-16 zhen-zheng Huang Plant media
EP2456454A4 (en) 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
WO2012091564A2 (en) 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
AU2014283221A1 (en) * 2013-06-20 2015-12-03 Novo Nordisk A/S GLP-1 derivatives and uses thereof
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
GB201403794D0 (en) * 2014-03-04 2014-04-16 Univ Manchester Novel antimicrobial peptides
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015197446A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
AU2015339134B2 (en) 2014-10-30 2021-06-17 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
CN106687128B (zh) 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
JP2019510739A (ja) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Gfral受容体療法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
WO2018071493A1 (en) 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN113474363A (zh) 2018-11-20 2021-10-01 詹森药业有限公司 用于降低体重和/或减少食物摄取量的gdf15类似物和方法

Also Published As

Publication number Publication date
EA202191105A1 (ru) 2021-08-03
EP3870211B1 (en) 2025-01-08
KR20210081389A (ko) 2021-07-01
US11713345B2 (en) 2023-08-01
CN113226351A (zh) 2021-08-06
BR112021007376A2 (pt) 2021-08-10
JP7539902B2 (ja) 2024-08-26
CL2021000987A1 (es) 2021-09-10
CA3116983A1 (en) 2020-04-30
JP2022513363A (ja) 2022-02-07
PH12021550885A1 (en) 2022-02-21
IL282297A (en) 2021-05-31
MX428581B (es) 2025-11-13
CN113226351B (zh) 2025-01-14
AU2025203071A1 (en) 2025-05-22
SA521421825B1 (ar) 2024-03-06
EP3870211C0 (en) 2025-01-08
WO2020084496A1 (en) 2020-04-30
SG11202103990QA (en) 2021-05-28
DOP2021000075A (cg-RX-API-DMAC10.html) 2021-12-15
JOP20210084A1 (ar) 2021-04-22
EP4520343A3 (en) 2025-05-21
MX2021004665A (es) 2021-08-24
US20250197468A1 (en) 2025-06-19
US12275770B2 (en) 2025-04-15
IL282297B1 (en) 2026-04-01
AU2019368816B2 (en) 2025-01-30
US20230322888A1 (en) 2023-10-12
PE20211078A1 (es) 2021-06-09
JP2024170428A (ja) 2024-12-10
ES3011982T3 (en) 2025-04-08
IL282297B2 (en) 2026-08-01
MY205905A (en) 2024-11-20
AU2019368816A1 (en) 2021-05-13
CN119751697A (zh) 2025-04-04
EP3870211A4 (en) 2022-08-10
EP4520343A2 (en) 2025-03-12
CR20210193A (es) 2021-06-15
ECSP21028914A (es) 2021-05-31
US20220089669A1 (en) 2022-03-24
EP3870211A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
ECSP21028914A (es) Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas
CO2023017754A2 (es) Polipéptidos modificados
ECSP064643A (es) Proteinas de fusion de glp-1
MX2019011599A (es) Moleculas quimericas y usos de las mismas.
MX2021005018A (es) Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
MX2022006018A (es) Nanoporos artificiales y usos y metodos relacionados con los mismos.
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
AR114476A1 (es) Proteínas de fusión del factor de diferenciación de crecimiento 15
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
WO2016115511A3 (en) Vegf variant polypeptide compositions
CO2020016008A2 (es) Formulación de proteína de fusión estable
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
MX2023001440A (es) Proteinas de fusion del ligando para flt3 y metodos de uso.
CL2017002687A1 (es) Polipéptidos dirigidos a la fusión de vih
MX2021011407A (es) Proteinas de dominio ccn recombinantes y proteinas de fusion.
EP4234573A4 (en) FUSION PROTEIN COMPRISING BP26 AND AN ANTIGENIC POLYPEPTIDE
IL321241A (en) Antibodies against the fusion protein (f) of metapneumovirus and their uses
PH12022553417A1 (en) Stabilized corona virus spike protein fusion proteins
BR112022013620A2 (pt) Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos
AR119550A1 (es) Motivos de la proteína de unión a rubisco y sus usos
AR108844A1 (es) Proteínas de fusión y su aplicación en la preparación de vacunas